Observational study on off-label use of tocilizumab in patients with severe COVID-19

This observational cohort study (n=44) found those treated with tocilizumab had a lower average respiratory rate than matched patients not receiving this treatment (21.5 vs 25.5 breaths/min at day 14, 95% CI −7.5 to −0.4; p=0.03), and they tended to be intubated less.


European Journal of Hospital Pharmacy